Đánh giá kết quả điều trị pembrolizumab bước sau trên bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn muộn

Assessing the treatment results and adverse events of second-line pembrolizumab for the treatment of recurrent/metastatic non-small cell lung cancer patients at National Cancer Hospital from 06/2017 to 10/2022. Patients and method: Retrospective and prospective analyses of 22 patients diagnosed of recurrent/ metastatic non-small cell lung carcinoma treated with second-line pembrolizumab at National Cancer Hospital from 06/2017 to 10/2022. Results: Partial response rate was 31.8%, stable disease rate was 40.9%. Disease-control rate was 72.7%. Mean progression-free survival (PFS) was 5.25±2.22 months (range, 2.25-22 months). There was no significant difference in PFS among patients with clinical and subclinical features. Rates of hyperthyroidism and hypothyroidism were similar, accounted for 9.1% of cases. All grades were grade 1. Conclusion: Second-line pembrolizumab improved the progression-free survival for the treatment of metastatic non-small lung cancer with a mean PFS of 5.25±2.22 months and disease-control rate was 72.7%.